Toru Fujikawa

905 total citations
13 papers, 709 citations indexed

About

Toru Fujikawa is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Toru Fujikawa has authored 13 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Cellular and Molecular Neuroscience and 2 papers in Oncology. Recurrent topics in Toru Fujikawa's work include Receptor Mechanisms and Signaling (11 papers), Neuropeptides and Animal Physiology (10 papers) and Pharmacological Receptor Mechanisms and Effects (3 papers). Toru Fujikawa is often cited by papers focused on Receptor Mechanisms and Signaling (11 papers), Neuropeptides and Animal Physiology (10 papers) and Pharmacological Receptor Mechanisms and Effects (3 papers). Toru Fujikawa collaborates with scholars based in Japan and United States. Toru Fujikawa's co-authors include Jian Jiang, M. Matsui, Shin-ichi Takahashi, Makoto M. Taketo, Hiroshi Karasawa, Toshiya Manabe, Toshifumi Kimura, Kazuhito Noguchi, Junko Itô and Norikazu Ohtake and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and Journal of Medicinal Chemistry.

In The Last Decade

Toru Fujikawa

13 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toru Fujikawa Japan	9	374	240	200	120	92	13	709
Agnès Choppin United States	14	434 1.2×	294 1.2×	307 1.5×	126 1.1×	61 0.7×	26	830
Kevin Monaghan United States	12	494 1.3×	148 0.6×	57 0.3×	157 1.3×	256 2.8×	18	890
Donald V. Daniels United States	12	497 1.3×	315 1.3×	171 0.9×	138 1.1×	19 0.2×	19	764
Hitomi Shinoura Japan	14	434 1.2×	225 0.9×	101 0.5×	135 1.1×	15 0.2×	21	702
John Lesnick United States	9	530 1.4×	330 1.4×	197 1.0×	151 1.3×	12 0.1×	12	846
Carlos Reguenga Portugal	15	471 1.3×	94 0.4×	45 0.2×	169 1.4×	53 0.6×	29	664
Yin Nam Kwok Canada	18	363 1.0×	375 1.6×	25 0.1×	108 0.9×	18 0.2×	52	909
Sung-Young Kim South Korea	7	218 0.6×	122 0.5×	12 0.1×	104 0.9×	140 1.5×	7	679
Thomas S. Heard United States	11	354 0.9×	100 0.4×	15 0.1×	94 0.8×	23 0.3×	15	646
Vasiliki Staikopoulos Australia	10	160 0.4×	83 0.3×	20 0.1×	161 1.3×	23 0.3×	17	430

Countries citing papers authored by Toru Fujikawa

Since Specialization

Citations

This map shows the geographic impact of Toru Fujikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toru Fujikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toru Fujikawa more than expected).

Fields of papers citing papers by Toru Fujikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toru Fujikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toru Fujikawa. The network helps show where Toru Fujikawa may publish in the future.

Co-authorship network of co-authors of Toru Fujikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Toru Fujikawa. A scholar is included among the top collaborators of Toru Fujikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toru Fujikawa. Toru Fujikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Moriya, Ryuichi, Toru Fujikawa, Junko Itô, et al.. (2009). Pancreatic polypeptide enhances colonic muscle contraction and fecal output through neuropeptide Y Y4 receptor in mice. European Journal of Pharmacology. 627(1-3). 258–264. 19 indexed citations

Itô, Junko, Masahiko Ito, Hirohide Nambu, et al.. (2009). Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell and Tissue Research. 338(2). 257–269. 61 indexed citations

Sagara, Takeshi, Sachie Otsuki, Toshifumi Kimura, et al.. (2006). Identification of a Novel 4-Aminomethylpiperidine Class of M₃Muscarinic Receptor Antagonists and Structural Insight into Their M₃Selectivity. Journal of Medicinal Chemistry. 49(19). 5653–5663. 8 indexed citations

Kimura, Toshifumi, et al.. (2003). Identification of novel muscarinic M3 selective antagonists with a conformationally restricted Hyp-Pro spacer. Bioorganic & Medicinal Chemistry Letters. 13(1). 57–60. 12 indexed citations

Ogino, Yoshio, Norikazu Ohtake, Kensuke Kobayashi, et al.. (2003). Muscarinic M3 receptor antagonists with (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2. Bioorganic & Medicinal Chemistry Letters. 13(13). 2167–2172. 12 indexed citations

Hirose, Hiroyasu, Ikuo Aoki, Toshifumi Kimura, et al.. (2002). The subtypes of muscarinic receptors for neurogenic bladder contraction in rats. European Journal of Pharmacology. 452(2). 245–253. 8 indexed citations

Sagara, Takeshi, Toshiaki Mase, Toshifumi Kimura, et al.. (2002). Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M₃ Antagonist Discriminating against the Other Receptor Subtypes. Journal of Medicinal Chemistry. 45(4). 984–987. 11 indexed citations

Matsui, M., Toru Fujikawa, Jian Jiang, et al.. (2002). Mice Lacking M₂and M₃Muscarinic Acetylcholine Receptors Are Devoid of Cholinergic Smooth Muscle Contractions But Still Viable. Journal of Neuroscience. 22(24). 10627–10632. 173 indexed citations

Torii, Akira, et al.. (2001). A rare case of primary adenoendocrine cell carcinoma of lower bile duct with anomalous creatine kinase isoenzyme and extremely high serum level of neuron specific enolase.. Nihon Naika Gakkai Zasshi. 90(8). 1525–1527. 4 indexed citations

10.

Hirose, Hiroyasu, Ikuo Aoki, Toshifumi Kimura, et al.. (2001). Pharmacological Properties of (2R)-N-[1-(6-Aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2- hydroxy-2-phenylacetamide: A Novel Muscarinic Antagonist with M2-Sparing Antagonistic Activity. Journal of Pharmacology and Experimental Therapeutics. 297(2). 790–797. 8 indexed citations

11.

Matsui, M., Hiroshi Karasawa, Toru Fujikawa, et al.. (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M ₃ subtype. Proceedings of the National Academy of Sciences. 97(17). 9579–9584. 351 indexed citations

12.

Mitsuya, Morihiro, Toshiaki Mase, Yoshimi Tsuchiya, et al.. (1999). J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors. Bioorganic & Medicinal Chemistry. 7(11). 2555–2567. 39 indexed citations

13.

Sato, Akio, Ikuo Aoki, Toru Fujikawa, et al.. (1999). Pharmacological characterization of J-104129, a novel muscarinic M3 receptor antagonist with high selectivity over M2 receptors. The Japanese Journal of Pharmacology. 79. 48–48. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact